Digene develops, manufactures and markets proprietary DNA and RNA tests focused on women’s cancers and infectious diseases. The company's flagship product, the Digene HPV test, is the only FDA-approved test for the human papillomavirus (HPV), the primary cause of cervical cancer. Digene’s product portfolio also includes DNA tests for other sexually transmitted infections, including chlamydia and gonorrhea, as well as tests for blood viruses. Headquartered in Gaithersburg, Md., Digene trades on the NASDAQ exchange [DIGE] and markets its tests in more than 40 countries worldwide. Digene now employees over 500 people and recently announced that it was being purchased by Qiagene for $1.6 billion in stock and cash.
The purpose of the annual Maryland Incubator Company of the Year Awards is to publicly recognize achievements by current clients and graduates of Maryland incubators and to provide a forum for the nominees to increase their visibility in the business, technology and investment communities.
ponsored by The Maryland Technology Development Corporation (TEDCO), RSM McGladrey, Maryland Department of Business & Economic Development (Maryland DBED), and Saul Ewing LLP, the ICOY awards are chosen in several categories by a selection committee of regional industry leaders and early-stage investors.